e-learning
resources
Virtual 2020
Pre-Congress Content
Genetics and biomarkers for diagnosis and prognosis of granulomatous lung diseases
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Markers of resistance to corticosteroids therapy in patients with pulmonary sarcoidosis
K. Shvets (Ivano-Frankivsk, Ukraine), M. Ostrovskyy (Ivano-Frankivsk, Ukraine), I. Savelikhina (Ivano-Frankivsk, Ukraine), O. Varunkiv (Ivano-Frankivsk, Ukraine), G. Korzh (Ivano-Frankivsk, Ukraine), K. Ostrovska (Ivano-Frankivsk, Ukraine)
Source:
Virtual Congress 2020 – Genetics and biomarkers for diagnosis and prognosis of granulomatous lung diseases
Session:
Genetics and biomarkers for diagnosis and prognosis of granulomatous lung diseases
Session type:
E-poster session
Number:
1088
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
K. Shvets (Ivano-Frankivsk, Ukraine), M. Ostrovskyy (Ivano-Frankivsk, Ukraine), I. Savelikhina (Ivano-Frankivsk, Ukraine), O. Varunkiv (Ivano-Frankivsk, Ukraine), G. Korzh (Ivano-Frankivsk, Ukraine), K. Ostrovska (Ivano-Frankivsk, Ukraine). Markers of resistance to corticosteroids therapy in patients with pulmonary sarcoidosis. 1088
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Safety of corticosteroid therapy in patients with pulmonary sarcoidosis
Source: International Congress 2017 – The many faces of sarcoidosis
Year: 2017
Inhaled treprostinil therapy in patients with pulmonary hypertension and parenchymal lung disease
Source: Annual Congress 2011 - Treatment of pulmonary hypertension
Year: 2011
Pulmonary and systemic inflammatory response in patients with pulmonary infections receiving long-term glucocorticoid therapy
Source: Eur Respir J 2002; 20: Suppl. 38, 15s
Year: 2002
Inhaled corticosteroids and the risk of a first exacerbation in COPD patients
Source: Eur Respir J 2004; 23: 692-697
Year: 2004
Pulse therapy of corticosteroids in idiopathic pulmonary fibrosis
Source: Annual Congress 2010 - Clinical aspects in pulmonary fibrosis
Year: 2010
The course of COVID-19 in pulmonary sarcoidosis patients, receiving methotrexate
Source: Virtual Congress 2021 – Moving forward in various aspects of sarcoidosis
Year: 2021
Inhaled antibiotic therapy in patients with severe asthma
Source: Virtual Congress 2021 – Advances in asthma treatment
Year: 2021
Effects of oral dual ERA therapy on pulmonary function testing and 6MWT in patients with idiopathic pulmonary fibrosis and pulmonary hypertension
Source: Annual Congress 2012 - Pulmonary circulation: clinical aspects of PAH and associated PH
Year: 2012
Long-term response to prednisone in newly treated patients with pulmonary sarcoidosis
Source: Virtual Congress 2021 – Better understanding of sarcoidosis: new keys
Year: 2021
The effect of augmentation therapy on systemic and pulmonary inflammation markers in α1-antitrypsin deficiency patients
Source: Annual Congress 2010 - Recent developments of molecular pathology and functional genomics in non-neoplastic and neoplastic lung diseases
Year: 2010
Combination treatment with nintedanib and prednisolone for patients with idiopathic pulmonary fibrosis
Source: International Congress 2018 – Management of idiopathic interstitial pneumonias: established and new treatments
Year: 2018
Compliance with nebulized therapy in patients with chronic lung disease
Source: Eur Respir J 2001; 18: Suppl. 33, 59s
Year: 2001
Response to PAH specific therapy in systemic sclerosis patients with extensive parenchymal changes and pulmonary hypertension
Source: Virtual Congress 2020 – Pulmonary hypertension in lung diseases
Year: 2020
Treatment failure of hospitalized patients with COPD exacerbation using systemic corticosteroids plus antibiotics: Role of early inflammatory predictors
Source: International Congress 2014 – Asthma and COPD management
Year: 2014
Effects of pulmonary rehabilitation on systemic and pulmonary inflammation in COPD patients
Source: Annual Congress 2010 - Exercise in COPD
Year: 2010
Influence of inhaled bronchodilator therapy on bacterioexcretion and LQ in patients with pulmonary TB infection with concomitant broncho-obstructive syndrome
Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions
Year: 2011
Pulmonary function test changes after cessation of inhaled corticosteroid therapy in asthma patients
Source: Annual Congress 2012 - Aspects of clinical asthma
Year: 2012
Evolution of systemic response in patients with pulmonary sarcoidosis of different course of the disease during anti-inflammatory treatment
Source: Annual Congress 2009 - Sarcoidosis in review
Year: 2009
Effects of pulmonary rehabilitation on systemic inflammation in patients with advanced COPD
Source: Eur Respir J 2005; 26: Suppl. 49, 721s
Year: 2005
Rituximab in the treatment of refractory pulmonary sarcoidosis
Source: Eur Respir J 2014; 43: 1525-1528
Year: 2014
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept